Multicenter Trial of ECMO in Children With Severe Cardiac Failure Using the Cardiohelp System
Launched by STANFORD UNIVERSITY · Oct 6, 2023
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
This clinical trial is studying the safety and effectiveness of a device called the Cardiohelp System, which is used for a treatment called VA-ECMO in children who have severe heart failure. The main goal is to see how well this device works in helping children recover and whether it is safe to use. Researchers will also be looking at how the device performs in young patients compared to established standards from previous studies.
Children aged 0 to 16 years and weighing between 3 to 80 kilograms who are experiencing serious heart problems may be eligible to participate. Before they join, parents or guardians will be asked to give their permission. Participants will be monitored closely for 30 days to track their recovery and any serious side effects, such as bleeding or stroke. It’s important to know that this trial is not currently recruiting participants, so those interested will need to wait for it to begin.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age 0 to 16 years of age
- • 2. Body weight 3 to 80 kilograms
- • 3. VA-ECMO use for primary cardiac failure using the Cardiohelp system.
- • 4. First ECMO run during any hospitalization
- • 5. Written informed consent from the parent or legally authorized representative.
- Exclusion Criteria:Children must not meet any of the following exclusion criteria within 48 hours prior to device implant:
- • 1. Gestational Age \<37 weeks
- • 2. Bleeding or coagulopathy that is a contraindication to anticoagulation
- • 3. Irreversible renal, hepatic or lung failure
- • 4. Stroke or uncertain neurological status within the past 30 days
- • 5. Severely malnourished
- • 6. Use of an ECMO system other than the Cardiohelp
- • 7. VV-ECMO or ECMO for primary respiratory failure
- • 8. Goals of patient to focus on comfort measures only.
- • 9. Failure to separate from cardiopulmonary bypass
About Stanford University
Stanford University is a prestigious academic institution renowned for its cutting-edge research and innovation in healthcare and medicine. As a clinical trial sponsor, Stanford leverages its extensive resources, including a collaborative network of world-class researchers and state-of-the-art facilities, to advance medical knowledge and improve patient care. The university is committed to conducting rigorous, ethical research that adheres to the highest standards of scientific integrity, fostering an environment where groundbreaking discoveries can translate into effective clinical applications. Through its clinical trials, Stanford aims to address critical health challenges and contribute to the development of novel therapies and treatment strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seattle, Washington, United States
Palo Alto, California, United States
Durham, North Carolina, United States
New York, New York, United States
Dallas, Texas, United States
Patients applied
Trial Officials
Lynn Sleeper, ScD
Principal Investigator
Boston Children's Hospital
Caroline Ozment, MD
Principal Investigator
Duke University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported